: Amyloidosis is a systemic disease due to the accumulation of misfolded amyloid fibrils that damage the heart and worsen the prognosis. Heart failure (HF), a condition frequently linked with an advanced stage of this disease, is the most prevalent clinical manifestation that leads to its diagnosis. However, due to the growing awareness of the occurrence of cardiac amyloidosis (CA), it is now possible to perform an early diagnosis and have a positive impact on its natural course. This study aims to highlight the most compelling issues concerning patients' clinical management with HF and CA.
Standard Therapy in Cardiac Amyloidosis / Del Franco, Annamaria; Biagioni, Giulia; Mazzoni, Carlotta; Argirò, Alessia; Zampieri, Mattia; Cappelli, Francesco. - In: HEART FAILURE CLINICS. - ISSN 1551-7136. - STAMPA. - 20:(2024), pp. 325-331. [10.1016/j.hfc.2024.03.004]
Standard Therapy in Cardiac Amyloidosis
Del Franco, Annamaria;Biagioni, Giulia;Mazzoni, Carlotta;Zampieri, Mattia;Cappelli, Francesco
2024
Abstract
: Amyloidosis is a systemic disease due to the accumulation of misfolded amyloid fibrils that damage the heart and worsen the prognosis. Heart failure (HF), a condition frequently linked with an advanced stage of this disease, is the most prevalent clinical manifestation that leads to its diagnosis. However, due to the growing awareness of the occurrence of cardiac amyloidosis (CA), it is now possible to perform an early diagnosis and have a positive impact on its natural course. This study aims to highlight the most compelling issues concerning patients' clinical management with HF and CA.File | Dimensione | Formato | |
---|---|---|---|
review non disease modifyng therapy.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
686.82 kB
Formato
Adobe PDF
|
686.82 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.